Sakai, Japan

Kohei Takenaka

This inventor holds 5 USPTO granted patents. Top assignee: Fujisawa Pharmaceutical Company, Ltd.. Active years: 1990-2002.


% Patents Active = 100.0

Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 99(Granted Patents)


Company Filing History:


Years Active: 1990-2002

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Kohei Takenaka: Innovator in Pharmaceutical Chemistry

Introduction

Kohei Takenaka is a prominent inventor based in Sakai, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds for medical applications. With a total of five patents to his name, Takenaka has established himself as a key figure in his industry.

Latest Patents

Among his latest patents, Takenaka has focused on the creation of guanidine derivatives and benzopyran derivatives. These compounds are notable for their processes of preparation and their effectiveness in treating hypertension. His work in this area demonstrates his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Takenaka is currently employed at Fujisawa Pharmaceutical Company, Ltd., where he continues to push the boundaries of pharmaceutical research. His role at the company allows him to collaborate with other talented professionals and contribute to groundbreaking projects that have the potential to change lives.

Collaborations

Throughout his career, Takenaka has worked alongside esteemed colleagues such as Youichi Shiokawa and Koichi Takimoto. These collaborations have fostered an environment of innovation and creativity, leading to the successful development of new pharmaceutical products.

Conclusion

Kohei Takenaka's work in pharmaceutical chemistry exemplifies the spirit of innovation and dedication to improving health outcomes. His contributions through patents and collaborations highlight the importance of research in the medical field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…